Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Liabilities and Shareholders Equity: 2020-2022

Historic Liabilities and Shareholders Equity for Terns Pharmaceuticals (TERN) over the last 3 years, with Dec 2022 value amounting to $287.0 million.

  • Terns Pharmaceuticals' Liabilities and Shareholders Equity rose 41.07% to $271.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.1 billion, marking a year-over-year increase of 73.62%. This contributed to the annual value of $287.0 million for FY2022, which is 70.78% up from last year.
  • As of FY2022, Terns Pharmaceuticals' Liabilities and Shareholders Equity stood at $287.0 million, which was up 70.78% from $168.1 million recorded in FY2021.
  • Terns Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $287.0 million for FY2022, and its period low was $92.3 million during FY2020.
  • Over the past 3 years, Terns Pharmaceuticals' median Liabilities and Shareholders Equity value was $168.1 million (recorded in 2021), while the average stood at $182.5 million.
  • Data for Terns Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 82.11% (in 2021) over the last 5 years.
  • Terns Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $92.3 million in 2020, then skyrocketed by 82.11% to $168.1 million in 2021, then spiked by 70.78% to $287.0 million in 2022.